2500.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 lapkr. 2023 @ 10:08):

Stats
Dzisiejszy wolumen	6.42M
Średni wolumen	0.00
Kapitalizacja rynkowa	2.46B
EPS	HKD0 ( 2024-03-29 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-3.09
ATR14	HKD0.268 (4.77%)

Wolumen Korelacja

Długi: 0.12 (neutral)

Krótki: 0.00 (neutral)

Signal:(64.926) Neutral

Venus MedTech HangZhou Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Venus MedTech HangZhou Korelacja - Waluta/Towar

-0.21
( neutral )

-0.35
( neutral )

0.09
( neutral )

-0.23
( neutral )

-0.17
( neutral )

Venus MedTech HangZhou Finanse

Annual	2023
Przychody:	HKD491.37M
Zysk brutto:	HKD389.21M (79.21 %)
EPS:	HKD-1.650

FY	2023
Przychody:	HKD491.37M
Zysk brutto:	HKD389.21M (79.21 %)
EPS:	HKD-1.650

FY	2022
Przychody:	HKD406.46M
Zysk brutto:	HKD314.00M (77.25 %)
EPS:	HKD-2.56

FY	2021
Przychody:	HKD415.86M
Zysk brutto:	HKD324.34M (77.99 %)
EPS:	HKD-0.850

Financial Reports:

No articles found.

Venus MedTech HangZhou

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.